KRAS and neoplasm: p53, LKB1 and K-Ras status have been proposed as markers of metformin action but, as discussed, pre-clinical studies remain divided on this issue with evidence suggesting that metformin has wide anti-tumor activity independent of the expression levels or mutation status of these signal mediators.